Table 3.
The association of patient characteristics and outcomes.
| Variable | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p-Value | HR | 95%CI | p-Value | |
| ADAMTS13:AC | 0.99 | 0.950–1.023 | 0.4409 | |||
| VWF:Ag | 1.00 | 1.000–1.002 | 0.2601 | |||
| VWF:Ag/ADAMTS13:AC | 1.01 | 0.999–1.012 | 0.0789 | 1.01 | 1.001–1.009 | 0.0261 |
| CLIF-C ACLF score | 1.17 | 1.078–1.273 | 0.0002 | 1.19 | 1.039–1.404 | 0.0138 |
| Creatinine | 1.63 | 1.152–2.296 | 0.0057 | 1.20 | 0.610–2.401 | 0.5844 |
| C-reactive protein | 1.04 | 0.925–1.176 | 0.4956 | |||
| MELD score | 1.10 | 1.039–1.172 | 0.0013 | 0.96 | 0.803–1.156 | 0.6885 |
The analysis was evaluated using Cox proportional hazards regression analysis. ADAMTS13, a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13; ADAMTS13:AC, ADAMTS13 activity; VWF, von Willebrand factor; VWF:Ag, VWF antigen; VWF:Ag/ADAMTS13:AC, the ratio of VWF:Ag to ADAMTS13:AC; CLIF-C, the chronic liver failure consortium; ACLF, acute-on-chronic liver failure; MELD, model for end-stage liver disease; HR, hazard ratio; CI, confidence interval.